EMBLAVEO (Avibactam Sodium; Aztreonam) Patent Expiration, LOE Window & CMS Spending

EMBLAVEO (Avibactam Sodium; Aztreonam) by AbbVie: FDA Orange Book core substance LOE 2032-06-15 (last listed 2033-02-07), 0 AB generics, $0 2024 CMS Part D & Medicaid spend, and $3,270 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorAbbVie
FDA Application & PathwayN217906 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE Date2032-06-15
Last Listed Patent or Exclusivity Date2033-02-07
Orange Book Patents (*PED Extensions)7 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$0
2024 Medicare Part D Spend$0
2024 Medicaid Spend$0
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($3,270 intro WAC)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for AbbVie across sibling Meru public-data platforms.